Search

Your search keyword '"van den Reek, Juul M.P.A."' showing total 19 results
Start Over Author "van den Reek, Juul M.P.A."
19 results on '"van den Reek, Juul M.P.A."'

4. Impairment in work and activities of daily life in patients with psoriasis: results of the prospective BioCAPTURE registry

Author

UMC Utrecht Holding, MS Dermatologie/Allergologie, van Hal, Tamara W., van den Reek, Juul M.P.A., Wenink, Mark H., Otero, Marisol E., Ossenkoppele, Paul M., Njoo, Marcellus D., Oostveen, Annet, Peters, Bas, Tjioe, Milan, Kop, Else N., Körver, John E.M., Dodemont, Sharon R.P., Kleinpenning, Marloes M., Berends, Maartje A.M., Veldkamp, Wendelien R., van Doorn, Martijn B.A., Mommers, Johannes M., Lindhout, Robert Jan, Kuijpers, Astrid L.A., van Lümig, Paula P., de Jonge, C. (Els) J., Tupker, Ron A., Hendricksen, Judith, Keijsers, Romy R., van den Hoogen, Frank H.J., Vriezekolk, Johanna E., de Jong, Elke M.G.J., UMC Utrecht Holding, MS Dermatologie/Allergologie, van Hal, Tamara W., van den Reek, Juul M.P.A., Wenink, Mark H., Otero, Marisol E., Ossenkoppele, Paul M., Njoo, Marcellus D., Oostveen, Annet, Peters, Bas, Tjioe, Milan, Kop, Else N., Körver, John E.M., Dodemont, Sharon R.P., Kleinpenning, Marloes M., Berends, Maartje A.M., Veldkamp, Wendelien R., van Doorn, Martijn B.A., Mommers, Johannes M., Lindhout, Robert Jan, Kuijpers, Astrid L.A., van Lümig, Paula P., de Jonge, C. (Els) J., Tupker, Ron A., Hendricksen, Judith, Keijsers, Romy R., van den Hoogen, Frank H.J., Vriezekolk, Johanna E., and de Jong, Elke M.G.J.

Published
2024

5. Impairment in work and activities of daily life in patients with psoriasis:results of the prospective BioCAPTURE registry

Author

van Hal, Tamara W., van den Reek, Juul M.P.A., Wenink, Mark H., Otero, Marisol E., Ossenkoppele, Paul M., Njoo, Marcellus D., Oostveen, Annet, Peters, Bas, Tjioe, Milan, Kop, Else N., Körver, John E.M., Dodemont, Sharon R.P., Kleinpenning, Marloes M., Berends, Maartje A.M., Veldkamp, Wendelien R., van Doorn, Martijn B.A., Mommers, Johannes M., Lindhout, Robert Jan, Kuijpers, Astrid L.A., van Lümig, Paula P., de Jonge, C. (Els) J., Tupker, Ron A., Hendricksen, Judith, Keijsers, Romy R., van den Hoogen, Frank H.J., Vriezekolk, Johanna E., de Jong, Elke M.G.J., van Hal, Tamara W., van den Reek, Juul M.P.A., Wenink, Mark H., Otero, Marisol E., Ossenkoppele, Paul M., Njoo, Marcellus D., Oostveen, Annet, Peters, Bas, Tjioe, Milan, Kop, Else N., Körver, John E.M., Dodemont, Sharon R.P., Kleinpenning, Marloes M., Berends, Maartje A.M., Veldkamp, Wendelien R., van Doorn, Martijn B.A., Mommers, Johannes M., Lindhout, Robert Jan, Kuijpers, Astrid L.A., van Lümig, Paula P., de Jonge, C. (Els) J., Tupker, Ron A., Hendricksen, Judith, Keijsers, Romy R., van den Hoogen, Frank H.J., Vriezekolk, Johanna E., and de Jong, Elke M.G.J.

Abstract

Background: Little is known about the extent of impairments in work and activities of daily life (ADL) in patients with psoriasis, and the influence of contextual factors such as disease-related characteristics and treatment. Therefore, this study aimed to assess these impairments in patients with psoriasis who started using biologicals/small molecule inhibitors. Methods: Using data from the prospective BioCAPTURE registry, we collected patient, disease, and treatment parameters, as well as work/ADL impairments at baseline, 6 and 12 months. Changes in impairment parameters and correlations between impairment and patient/disease characteristics were assessed using generalized estimating equations. Results: We included 194 patients in our analysis. After biological initiation, disease activity decreased significantly (PASI 11.2 at baseline versus 3.9 at 12 months, p < 0.001). Work-for-pay in this cohort was lower than in the Dutch general population (53% versus 67%, p = 0.01). In patients who had work-for-pay, presenteeism improved over time (5% at baseline versus 0% at 12 months, p = 0.04). Up to half of the patients reported impairments in ADL, which did not change over time. Associations between impairments and contextual factors varied, but all impairments were associated with worse mental/physical general functioning. Conclusion: Patients with psoriasis using biologicals are less likely to have work-for-pay. Treatment improves the work productivity of employed patients, but we were unable to detect changes in ADL performance.

Published
2024

6. Guselkumab induction therapy demonstrates long-lasting efficacy in patients with mild psoriasis, results from a randomized, placebo-controlled exploratory clinical trial

Author

Rousel, Jannik, primary, Bergmans, Menthe E., additional, van der Meulen, Laura W.J., additional, Pagan, Lisa, additional, de Bruin, Digna T., additional, de Kam, Marieke L., additional, Klarenbeek, Naomi B., additional, Bouwstra, Joke A., additional, Seyger, Marieke M.B., additional, van den Reek, Juul M.P.A., additional, Niemeyer-van der Kolk, Tessa, additional, Rissmann, Robert, additional, and van Doorn, Martijn B.A., additional

Published
2024
Full Text
View/download PDF

9. Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis:Three-year follow-up data of a single-blind randomized controlled trial

Author

van Huizen, Astrid M., van der Kraaij, Gayle E., Busard, Celine I., Ouwerkerk, Wouter, van den Reek, Juul M.P.A., Menting, Stef P., Prens, Errol P., Rispens, Theo, de Vries, Annick, de Jong, Elke M.G.J., Lambert, Jo, van Doorn, Martijn B.A., Spuls, Phyllis I., van Huizen, Astrid M., van der Kraaij, Gayle E., Busard, Celine I., Ouwerkerk, Wouter, van den Reek, Juul M.P.A., Menting, Stef P., Prens, Errol P., Rispens, Theo, de Vries, Annick, de Jong, Elke M.G.J., Lambert, Jo, van Doorn, Martijn B.A., and Spuls, Phyllis I.

Abstract

Background: Anti-drug antibodies (ADA) are formed in patients treated with adalimumab (ADL). This might increase clearance of ADL, potentially causing a (secondary) non-response. Combination therapy of ADL and methotrexate (MTX) reduces ADA levels and has a clinical benefit in rheumatologic diseases. In psoriasis however, the long-term effectiveness and safety have not been studied. Objectives: To investigate the three-year follow-up data of ADL combined with MTX compared to ADL monotherapy in ADL-naive patients with moderate to severe plaque type psoriasis. Methods: We conducted a multicentre RCT in the Netherlands and Belgium. Randomization was performed by a centralized online randomization service. Patients were seen every 12 weeks until week 145. Outcome assessors were blinded. We collected data on drug survival, effectiveness, safety, pharmacokinetics and immunogenicity of patients that started ADL combined with MTX compared to ADL monotherapy. We present descriptive analysis and patients were analysed according to the group initially randomized to. Patients becoming non-adherent to the biologic were excluded from analyses. Results: Sixty-one patients were included and 37 patients (ADL group n = 17, ADL + MTX group n = 20) continued in the follow-up study after 1 year. After 109 weeks and 145 weeks, there was a trend towards longer drug survival in the ADL + MTX group compared to the ADL group (week 109: 54.8% vs. 41.4%; p = 0.326, week 145: 51.6% vs. 41.4%; p = 0.464). At week 145, 7/13 patients were treated with MTX. In the ADL group, 4/12 patients that completed the study developed ADA, and 3/13 in the ADL + MTX group. Conclusions: In this small study, there was no significant difference in ADL overall drug survival when it was initially combined with MTX, compared to ADL alone. Discontinuation due to adverse events was common in the combination group. To secure accessible healthcare, combination treatment of ADL and MTX can be considered in individual p

Published
2023

13. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis

Author

van Huizen, Astrid M., Menting, Stef P., Gyulai, Rolland, Iversen, Lars, van der Kraaij, Gayle E., Middelkamp-Hup, Maritza A., Warren, Richard B., Spuls, Phyllis I., Schejtman, Adrián A., Egeberg, Alexander, Firooz, Alireza, Kumar, Alur S., Oakley, Amanda, Foulkes, Amy, Ramos, Andrea Machado Coelho, Fougerousse, Anne-Claire, Čarija, Antoanela, Akman-Karakaş, Ayse, Horváth, Barbara, Fábos, Béata, Matlock, Benjamin Hidalgo, Claréus, Birgitta Wilson, Castro, Carla, Ferrándiz, Carlos, Correa, Carolina Cortés, Marchesi, Carolina, Goujon, Catherine, Gonzalez, Cesar, Maldonado-García, César, Hong, Chih-ho, Griffiths, Christopher E.M., Vestergaard, Christian, Echeverría, Christina Mariela, de la Cruz, Claudia, Conrad, Curdin, Törőcsik, Dániel, Drvar, Daniela Ledić, Balak, Deepak, Jullien, Denis, Appelen, Diebrecht, Kim, Dong Hyun, de Jong, Elke M.G.J., El Gamal, Emad, Laffitte, Emmanuel, Mahé, Emmanuel, Sonkoly, Enikö, Colombo, Erika Páez, Vilarrasa, Eva, Willaert, Fabienne, Novoa, Farah D., Handjani, Farhad, Valenzuela, Fernando, Vílchez-Márquez, Francisco, Gonzalez, Gabriela Otero, Krisztián, Gáspár, Damiani, Giovanni, Krnjević-Pezić, Gordana, Pellerano, Graciela, Carretero, Gregorio, Hunter, Hamish J. A., Riad, Hassan, Oon, Hazel H., Boonen, Hugo P.J., Moussa, Iftin Osman, García-Doval, Ignacio, Csányi, Ildíko, Brajac, Ines, Turchin, Irina, Grozdev, Ivan, Weinberg, Jeffrey M., Nicolopoulos, Jenny, Wells, Jillian, Lambert, Jo L.W., Ingram, John R., Prinz, Jörg Christoph, de Souza Sittart, José Alexandre, Sanchez, Jose Luis, Hsiao, Josephine Pa-Fan, Castro-Ayarza, Juan Raul, Maul, Julia-Tatjana, van den Reek, Juul M.P.A., Trčko, Katarina, Barber, Kirk, Reich, Kristian, Gebauer, Kurt Aaron, Khobzei, Kuzma, Maul, Lara V., Massari, Larisa Prpić, Fardet, Laurence, le Cleach, Laurence, Misery, Laurent, Chandrashekar, Laxmisha, Muresanu, Lidia Irinel, Lecluse, Lidian, Skov, Lone, Frez, Ma. Lorna, Babić, Lucija Tomić, Puig, Lluís, Gomez, Luis Castro, Ramam, M., Dutil, Maha, El-Sayed, Mahira Hamdy, Olszewska, Malgorzata, Schram, Mandy Elvira, Franco, Manuel Dario, Llamas-Velasco, Mar, Gonçalo, Margarida, Velásquez-Lopera, Margarita M., Abad, Maria Eugenia, de Oliveira, Maria de Fátima Santos Paim, Seyger, Marieke M. B., Kaštelan, Marija, Rademaker, Marius, Sikora, Mariusz, Lebwohl, Mark, Wiseman, Marni C., Ferran, Marta, van Doorn, Martijn, Danespazhooh, Maryam, Bylaitė-Bucinskiene, Matilda, Gooderham, Melinda J., Polić, Melita Vukšić, de Rie, Menno A., Zheng, Min, Gómez-Flores, Minerva, Salleras i Redonnet, Montse, Silverberg, Nanette B., Doss, Nejib, Yawalkar, Nikhil, Chosidow, Olivier, Zargari, Omid, de la Cueva, Pablo, Fernandez-Peñas, Pablo, Cárdenas Rojas, Paola J., Gisondi, Paolo, Grewal, Parbeer, Sator, Paul, Luna, Paula Carolina, Félix, Paulo Antonio Oldani, Varela, Paulo, Holló, Péter, Cetkovska, Petra, Calzavara-Pinton, Piergiacomo, Ghislain, Pierre-Dominique, Araujo, Raquel Ruiz, Romiti, Ricardo, Kui, Róbert, Čeović, Romana, Vender, Ronald, Lafuente-Urrez, Rosario Fátima, del-Río, Rubén, Gulin, Sandra J., Handa, Sanjeev, Mahil, Satveer K., Kolalapudi, Seetharam A., Marrón, Servando E., Azimi, Seyyede Zeinab, Janmohamed, Sherief R., da Cruz Costa, Sidney Augusto, Choon, Siew Eng, Urbancek, Slavomir, Ayanlowo, Olusola, Margasin, Susana M., Wong, Tak-Wah, Mälkönen, Tarja, Hurtová, Tatiana, Reciné, Tatiana Riveros, Huldt-Nystrøm, Theis, Torres, Tiago, Liu, Tong-Yun, Leonidze, Tsira, Sharma, Vinod Kumar, Weightman, Warren, Gulliver, Wayne, Veldkamp, Wendelien, Clinical sciences, Gerontology, Surgical clinical sciences, Dermatology, Skin function and permeability, AII - Inflammatory diseases, Graduate School, APH - Quality of Care, APH - Methodology, and APH - Personalized Medicine

Subjects
Adult, Consensus, International eDelphi Study, Patients, Methotrexate Dosing Regimen, Dermatology, THERAPY, Psoriasis/therapy, BRITISH-ASSOCIATION, DOUBLE-BLIND, Folic Acid, Surveys and Questionnaires, MANAGEMENT, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Dermatovenerologija, SYSTEMIC TREATMENT, Humans, Psoriasis, 610 Medicine & health, Child, Methotrexate, methotrexate in psoriasis, Other Research Radboud Institute for Health Sciences [Radboudumc 0], EFFICACY, RANDOMIZED-TRIAL, DERMATOLOGISTS GUIDELINES, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], CHRONIC PLAQUE PSORIASIS, MODERATE, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Dermatovenerology
Abstract

Contains fulltext : 251813.pdf (Publisher’s version ) (Closed access) IMPORTANCE: A clear dosing regimen for methotrexate in psoriasis is lacking, and this might lead to a suboptimal treatment. Because methotrexate is affordable and globally available, a uniform dosing regimen could potentially optimize the treatment of patients with psoriasis worldwide. OBJECTIVE: To reach international consensus among psoriasis experts on a uniform dosing regimen for treatment with methotrexate in adult and pediatric patients with psoriasis and identify potential future research topics. DESIGN, SETTING, AND PARTICIPANTS: Between September 2020 and March 2021, a survey study with a modified eDelphi procedure that was developed and distributed by the Amsterdam University Medical Center and completed by 180 participants worldwide (55 [30.6%] resided in non-Western countries) was conducted in 3 rounds. The proposals on which no consensus was reached were discussed in a conference meeting (June 2021). Participants voted on 21 proposals with a 9-point scale (1-3 disagree, 4-6 neither agree nor disagree, 7-9 agree) and were recruited through the Skin Inflammation and Psoriasis International Network and European Academy of Dermatology and Venereology in June 2020. Apart from being a dermatologist/dermatology resident, there were no specific criteria for participation in the survey. The participants worked mainly at a university hospital (97 [53.9%]) and were experienced in treating patients with psoriasis with methotrexate (163 [91.6%] had more than 10 years of experience). MAIN OUTCOMES AND MEASURES: In a survey with eDelphi procedure, we tried to reach consensus on 21 proposals. Consensus was defined as less than 15% voting disagree (1-3). For the consensus meeting, consensus was defined as less than 30% voting disagree. RESULTS: Of 251 participants, 180 (71.7%) completed all 3 survey rounds, and 58 participants (23.1%) joined the conference meeting. Consensus was achieved on 11 proposals in round 1, 3 proposals in round 2, and 2 proposals in round 3. In the consensus meeting, consensus was achieved on 4 proposals. More research is needed, especially for the proposals on folic acid and the dosing of methotrexate for treating subpopulations such as children and vulnerable patients. CONCLUSIONS AND RELEVANCE: In this eDelphi consensus study, consensus was reached on 20 of 21 proposals involving methotrexate dosing in patients with psoriasis. This consensus may potentially be used to harmonize the treatment with methotrexate in patients with psoriasis.

Published
2022
Full Text
View/download PDF

14. Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort

Author

Van Muijen, Marloes E., primary, Thomas, Sarah E., additional, Groenewoud, Hans M.M., additional, Otero, Marisol E., additional, Ossenkoppele, Paul M., additional, Njoo, Marcellus D., additional, Dodemont, Sharon R.P., additional, Kop, Else N., additional, Berends, Maartje A.M., additional, Koetsier, Marjolein I.A., additional, Mommers, Johannes M., additional, Körver, John E.M., additional, Tupker, Ron A., additional, De Bruin-Weller, Marjolein S., additional, Weppner-Parren, Lizelotte J.M.T., additional, Peters, Bas, additional, Kleinpenning, Marloes M., additional, Kuijpers, Astrid L.A., additional, Arnold, W. Peter, additional, Van Lümig, Paula P.M., additional, Van den Reek, Juul M.P.A., additional, and De Jong, Elke M.G.J., additional

Published
2022
Full Text
View/download PDF

16. Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources

Author

Davidson, Linda, primary, van den Reek, Juul M.P.A., additional, Bruno, Mariolina, additional, van Hunsel, Florence, additional, Herings, Ron M.C., additional, Matzaraki, Vasiliki, additional, Boahen, Collins K., additional, Kumar, Vinod, additional, Groenewoud, Hans M.M., additional, van de Veerdonk, Frank L., additional, Netea, Mihai G., additional, de Jong, Elke M.G.J., additional, and Kullberg, Bart Jan, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results